CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q3 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $504,964 | -19.1% | 11,125 | 0.0% | 0.01% | -23.1% |
| Q2 2023 | $624,558 | +24.1% | 11,125 | 0.0% | 0.01% | +30.0% |
| Q1 2023 | $503,184 | +102.1% | 11,125 | +81.6% | 0.01% | +150.0% |
| Q4 2022 | $248,981 | -37.8% | 6,125 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $400,000 | +7.5% | 6,125 | 0.0% | 0.01% | 0.0% |
| Q2 2022 | $372,000 | -3.1% | 6,125 | 0.0% | 0.01% | 0.0% |
| Q1 2022 | $384,000 | -17.2% | 6,125 | 0.0% | 0.01% | -20.0% |
| Q4 2021 | $464,000 | -32.4% | 6,125 | 0.0% | 0.01% | -37.5% |
| Q3 2021 | $686,000 | -30.8% | 6,125 | 0.0% | 0.02% | -20.0% |
| Q2 2021 | $992,000 | +33.0% | 6,125 | 0.0% | 0.02% | +17.6% |
| Q1 2021 | $746,000 | -20.5% | 6,125 | 0.0% | 0.02% | -45.2% |
| Q4 2020 | $938,000 | +83.2% | 6,125 | 0.0% | 0.03% | +47.6% |
| Q3 2020 | $512,000 | +13.8% | 6,125 | 0.0% | 0.02% | +31.2% |
| Q2 2020 | $450,000 | +107.4% | 6,125 | +19.5% | 0.02% | +60.0% |
| Q1 2020 | $217,000 | – | 5,125 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
| Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
| NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
| NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
| Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
| Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
| Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
| ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
| Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |